- Age ≥18 years - The following patient cohorts will be included: B-cell non Hodgkin lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myeloproliferative diseases (MPN), patients with hemoglobinopathies (sickle cell disease and thalassemia), patients who received cell therapy (autologous HCT, allogeneic HCT or CAR T-cell therapy) AND - Patients must either currently receive immuno-chemotherapy or have received such therapy in the past 6 months, or currently receive targeted agents, or have received autologous or allogeneic stem cell transplantation no longer than 6 months prior, or have received CAR-T therapy.

- Age ≥18 years - The following patient cohorts will be included: B-cell non Hodgkin lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myeloproliferative diseases (MPN), patients with hemoglobinopathies (sickle cell disease and thalassemia), patients who received cell therapy (autologous HCT, allogeneic HCT or CAR T-cell therapy) AND - Patients must either currently receive immuno-chemotherapy or have received such therapy in the past 6 months, or currently receive targeted agents, or have received autologous or allogeneic stem cell transplantation no longer than 6 months prior, or have received CAR-T therapy.